[1]Therapeutics and COVID-19:living guideline,16 September 2022.https://www.who.int/publications/i/item/WHO2019-nCoV-therapeutics-2022.5.[2]National Institutes of Health.Coronavirus disease 2019(COVID-19)treatment guidelines.https://covid19treatmentguidelines.nih.gov/.[3]新型冠状病毒肺炎诊疗方案(试行第九版).http://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf.[4]COVID-19:Evaluation of adults with acute illness in the outpatient setting.https://www.uptodate.com/contents/zhHans/covid-19-evaluation-of-adults-with-acute-illness-in-the-outpatientsetting?search=%E6%96%B0%E5%86%A0%E9%97%A8%E8%AF%8A&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.[5]COVID-19:Management in hospitalized adults.https://www.uptodate.com/contents/covid-19-management-inhospitalizedadults?search=%E6%96%B0%E5%86%A0%E4%BD%8F%E9%99%A2&source=Out%20of%20date%20-%20zhHans&selectedTitle=1~150.[6]RECOVERY Collaborative Group,Horby P,Lim WS,et al.Dexamethasone in hospitalized patients with COVID19.N Engl J Med 2021;384:693-704.[7]REMAP-CAP Investigators,Gordon AC,Mouncey PR,et al.Interleukin-6 receptor antagonists in critically illpatients with COVID-19.N Engl J Med 2021;384:1491-502.[8]Guimaraes PO,Quirk D,Furtado RH,et al.Tofacitinib in patients hospitalized with COVID-19 pneumonia.N Engl